NCT04758234View on ClinicalTrials.gov

A Study of LY3549492 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

February 22, 2021

Primary Completion Date

January 10, 2022

Study Completion Date

January 10, 2022

Conditions
Healthy
Interventions
DRUG

LY3549492

Administered orally.

DRUG

Placebo

Administered orally.

Trial Locations (1)

75247

Covance Dallas, Dallas

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04758234 - A Study of LY3549492 in Healthy Participants | Biotech Hunter | Biotech Hunter